Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 978 participants.

Also called NCT01117350

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 978 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01117350
  • EudraCT 2010-018437-21
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Brazil, Canada, Czechia, Finland, France, Greece, Ireland, Israel, Mexico, Netherlands, Russia, Slovakia, Spain, Sweden, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01117350. Randomized; no masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2014-01-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
Acronym
EAGLE
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Liraglutide
Intervention (Drug)
Metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01117350
Content hash
ce3943d1f849351dee0cda17cffacc16463ff8d47b5850f7b1965dd121bd1d83